Trials / Enrolling By Invitation
Enrolling By InvitationNCT05088694
The Optimization and Evaluation of the Extremism and Intolerance Curriculum for the Kingdom of Bahrain.
- Status
- Enrolling By Invitation
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,500 (estimated)
- Sponsor
- University of North Carolina, Greensboro · Academic / Other
- Sex
- All
- Age
- 11 Years – 18 Years
- Healthy volunteers
- Accepted
Summary
Researcher from UNC Greensboro have partnered with Prevention Strategies and key stakeholders from the Kingdom of Bahrain to conduct a study using the innovative, engineering-inspired methodological approach, the Multiphase Optimization Strategy (MOST), to optimize and evaluate the Peaceful Coexistence and Anti-Extremism middle and high school curricula. No other curriculum targeting tolerance and/or extremism has been optimized using the state-of-the-art MOST methodology. The overall goal of the project is that the optimized versions of Peaceful Coexistence and Anti-Extremism curricula will be used across the Kingdom of Bahrain and translated for use in other countries to combat the spread of extremism and intolerance. Additionally, the D.A.R.E. keepin' it REAL (kiR) and D.A.R.E. myPlaybook high school programs will be evaluated as part of the Peaceful Coexistence and Anti-Extremism evaluation.
Conditions
- Norm, Social
- Literacy
- Resistance Skills
- Beliefs About Consequences
- Decision Making Skills
- Empathy
- Tolerance
- Open Mindedness
- Active Citizenship
- Anti-extremism
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Peaceful Coexistence | The Peaceful Coexistence intervention seeks to target important risk and protective factors related to tolerance and acceptance. The Anti-Extremism intervention seeks to take the same risk and protective factors covered in the Peaceful Coexistence intervention and have students' psychosocial factors shift their skills and behavior. |
Timeline
- Start date
- 2021-11-01
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2021-10-22
- Last updated
- 2024-12-18
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT05088694. Inclusion in this directory is not an endorsement.